Article added to library!
Pubchase is a service of - free, open access, crowdsourced protocols repository. Explore protocols.
Sign in
Reset password
or connect with
By signing in you are agreeing to our
Terms Of Service and Privacy Policy
Dec 28, 2015
Zhongguo Shi Yan Xue Ye Xue Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal Of Experimental Hematology / Chinese Association Of Pathophysiology
In many countries the hypomethylating agents (HMAs) are the major compounds to treat patients suffering from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with low bone marrow blast counts. The elderly AML patients with poor performance status and comorbidity also benefit from HMAs. Patients who resist to HMA have a poorer outcome as compared to sensitive patients. Therefore, the reliable markers for predicting response to HMAs are urgeatly needed in clinic. In this review, the biomarkers for predicting response of patients with MDS or AML to HMAs are summarized.

Downloading PDF to your library...

Uploading PDF...

PDF uploading

Delete tag:

The link you entered does not seem to be valid

Please make sure the link points to contains a valid shared_access_token